The document describes research done to improve the isolation, derivatization, and characterization of new mithramycin analogues (MTM SA, MTM SK, and MTM SDK) for potential anticancer use. MTM SA was successfully isolated from the other analogues using an anion exchange column that took advantage of MTM SA's negative charge at physiological pH. Derivatives of MTM SA were then created by attaching amino acid side chains using coupling agents, and analysis showed new peaks indicating the formation of MTM SA derivatives. The toxicity of these new compounds will be further investigated using human leukemia cell lines.